Ascendis gets USD 150m in cash from selling synthetic royalty

Biotech company Ascendis and Royalty Pharma have entered into an agreement that secures the former an upfront payment of USD 150m.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app